Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cellectis S.A. stock logo
CLLS
Cellectis
$2.85
+2.9%
$2.13
$1.10
$3.24
$158.41M3.03246,644 shs17,913 shs
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
$1.85
+0.5%
$1.73
$0.66
$3.00
$172.28M2.551.27 million shs1.40 million shs
Journey Medical Corporation stock logo
DERM
Journey Medical
$7.47
+5.5%
$7.16
$3.54
$8.90
$174.02M0.8188,629 shs239,603 shs
Exicure, Inc. stock logo
XCUR
Exicure
$6.09
-1.8%
$7.05
$1.44
$36.00
$38.48M3.6773,592 shs8,762 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cellectis S.A. stock logo
CLLS
Cellectis
+2.89%0.00%+22.32%+93.88%+21.02%
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
+0.54%-6.57%-25.40%+81.37%-17.04%
Journey Medical Corporation stock logo
DERM
Journey Medical
+5.51%+7.48%+1.08%+6.71%+69.77%
Exicure, Inc. stock logo
XCUR
Exicure
-1.77%-8.42%-27.33%-39.34%+1,480.59%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cellectis S.A. stock logo
CLLS
Cellectis
3.3966 of 5 stars
3.55.00.00.03.32.50.0
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
2.8806 of 5 stars
3.55.00.00.02.11.70.0
Journey Medical Corporation stock logo
DERM
Journey Medical
1.6232 of 5 stars
3.21.00.00.02.30.80.6
Exicure, Inc. stock logo
XCUR
Exicure
1.8927 of 5 stars
0.05.00.04.72.20.80.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cellectis S.A. stock logo
CLLS
Cellectis
3.00
Buy$4.0040.35% Upside
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
3.00
Buy$6.67260.36% Upside
Journey Medical Corporation stock logo
DERM
Journey Medical
2.33
Hold$11.7557.30% Upside
Exicure, Inc. stock logo
XCUR
Exicure
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest XCUR, CRBU, CLLS, and DERM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/15/2025
Journey Medical Corporation stock logo
DERM
Journey Medical
Zacks Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeHold ➝ Strong Sell
8/13/2025
Journey Medical Corporation stock logo
DERM
Journey Medical
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$9.00 ➝ $13.00
(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cellectis S.A. stock logo
CLLS
Cellectis
$49.22M3.22N/AN/A$1.75 per share1.63
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
$9.99M17.24N/AN/A$1.78 per share1.04
Journey Medical Corporation stock logo
DERM
Journey Medical
$56.13M3.10N/AN/A$0.83 per share9.00
Exicure, Inc. stock logo
XCUR
Exicure
$500K76.98N/AN/A$1.40 per share4.35
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cellectis S.A. stock logo
CLLS
Cellectis
-$36.76M-$0.82N/AN/AN/A-100.69%-68.05%-21.53%11/3/2025 (Estimated)
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
-$149.10M-$1.78N/AN/AN/A-1,800.93%-62.35%-49.65%11/5/2025 (Estimated)
Journey Medical Corporation stock logo
DERM
Journey Medical
-$14.67M-$0.38N/AN/AN/A-15.49%-48.69%-11.26%11/11/2025 (Estimated)
Exicure, Inc. stock logo
XCUR
Exicure
-$9.70M-$3.88N/AN/AN/A-192.16%-84.30%N/A

Latest XCUR, CRBU, CLLS, and DERM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
-$0.40-$0.35+$0.05-$0.58$1.64 million$2.67 million
8/12/2025Q2 2025
Journey Medical Corporation stock logo
DERM
Journey Medical
-$0.07-$0.16-$0.09-$0.16$14.93 million$15.01 million
8/8/2025Q2 2025
Exicure, Inc. stock logo
XCUR
Exicure
N/A-$0.41N/A-$0.41N/AN/A
8/4/2025Q2 2025
Cellectis S.A. stock logo
CLLS
Cellectis
-$0.15-$0.24-$0.09-$0.24$10.07 million$18.19 million
6/27/2025Q1 2025
Exicure, Inc. stock logo
XCUR
Exicure
N/A-$0.45N/A$0.49N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cellectis S.A. stock logo
CLLS
Cellectis
N/AN/AN/AN/AN/A
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
N/AN/AN/AN/AN/A
Journey Medical Corporation stock logo
DERM
Journey Medical
N/AN/AN/AN/AN/A
Exicure, Inc. stock logo
XCUR
Exicure
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cellectis S.A. stock logo
CLLS
Cellectis
0.58
1.38
1.38
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
N/A
6.66
6.66
Journey Medical Corporation stock logo
DERM
Journey Medical
1.11
1.27
0.95
Exicure, Inc. stock logo
XCUR
Exicure
N/A
1.89
1.89

Institutional Ownership

CompanyInstitutional Ownership
Cellectis S.A. stock logo
CLLS
Cellectis
63.90%
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
77.51%
Journey Medical Corporation stock logo
DERM
Journey Medical
7.25%
Exicure, Inc. stock logo
XCUR
Exicure
42.82%

Insider Ownership

CompanyInsider Ownership
Cellectis S.A. stock logo
CLLS
Cellectis
16.41%
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
8.28%
Journey Medical Corporation stock logo
DERM
Journey Medical
15.03%
Exicure, Inc. stock logo
XCUR
Exicure
3.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cellectis S.A. stock logo
CLLS
Cellectis
29055.58 million46.46 millionOptionable
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
10093.12 million85.41 millionOptionable
Journey Medical Corporation stock logo
DERM
Journey Medical
9023.30 million19.80 millionN/A
Exicure, Inc. stock logo
XCUR
Exicure
506.32 million6.07 millionNot Optionable

Recent News About These Companies

Short Interest in Exicure, Inc. (NASDAQ:XCUR) Drops By 51.8%
Exicure Posts Wider Loss in Fiscal Q2
Stocks to Watch: Exicure, TTEC
Exicure Shares Up After Swing to Profit in 1Q
Why Exicure Inc. (XCUR) Soared on Monday

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cellectis stock logo

Cellectis NASDAQ:CLLS

$2.82 +0.05 (+1.81%)
As of 08/22/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Caribou Biosciences stock logo

Caribou Biosciences NASDAQ:CRBU

$1.85 +0.01 (+0.54%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$1.83 -0.02 (-1.08%)
As of 08/22/2025 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Journey Medical stock logo

Journey Medical NASDAQ:DERM

$7.47 +0.39 (+5.51%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$7.49 +0.02 (+0.27%)
As of 08/22/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.

Exicure stock logo

Exicure NASDAQ:XCUR

$6.09 -0.11 (-1.77%)
Closing price 08/22/2025 03:59 PM Eastern
Extended Trading
$6.07 -0.02 (-0.33%)
As of 08/22/2025 05:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.